How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,495 results for

High Pressure Injection Wound

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1481. Bevacizumab and Irinotecan for Patients With Primary Brain Tumors and Progression After Standard Therapy

procedures, fine needle aspirations or core biopsies within 7 days prior to day 0 History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 month prior to day 0 History of known HIV, Hepatitis B and Hepatitis C negative Any ongoing infection, uncontrolled diabetes mellitus, serious non-healing wound, ulcer or bone fracture Pregnancy or breast feeding Requires therapeutic anti-coagulation Blood pressure > 150/100 mmHG Grade 2 or greater proteinuria Contacts (...) 29, 2011 Sponsor: Rigshospitalet, Denmark Information provided by: Rigshospitalet, Denmark Study Details Study Description Go to Brief Summary: Irinotecan has demonstrated activity in malignant gliomas in multiple phase II studies. The activity is limited, with an approximately 15 % response rate and a progression-free survival of 3-5 months. Given the synergy between irinotecan and bevacizumab in colorectal cancer, and the high-level expression of vascular endothelial growth factor on malignant

2007 Clinical Trials

1482. Proton Therapy and Bevacizumab for Primary Liver Tumors

to radiographic progression and 2 year survival rate. To analyze dose-volume characteristics that influence the development of radiation induced liver disease (RILD) and GI bleeds that may occur. To assess quality of life during and after chemoradiation therapy. Condition or disease Intervention/treatment Phase Liver Cancer Hepatocellular Carcinoma Cholangiocarcinoma Drug: Bevacizumab Radiation: Proton Radiation Therapy Phase 1 Detailed Description: Proton beams are designed to deliver a high dose (...) anticoagulation treatment with coumadin, low molecular weight heparin or IV heparin. Evidence of bleeding diathesis or coagulopathy. Anticoagulation for line maintenance is permitted. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0, or anticipation of need for major surgical procedure during the course of the study; fine needle aspirations or core biopsies within 7 days prior to Day 0. Serious, nonhealing wound, ulcer, or bone fracture. Clinically

2007 Clinical Trials

1483. Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults

eye diseases or other conditions that require the use of corticosteroid eye drops. known/history of cardiac disease. subjects who have been diagnosed with 3 or more of the following risk factors for ischemic coronary disease: a) high blood pressure b) elevated blood cholesterol levels c) diabetes or high blood sugar d) first degree relative (for example, mother, father, brother, or sister) who had a heart condition before the age of 50 e) smoke cigarettes subjects with a history of palpitations (...) Completion Date : October 2006 Actual Study Completion Date : October 2006 Resource links provided by the National Library of Medicine related topics: resources: Arms and Interventions Go to Arm Intervention/treatment Experimental: A MVA3000 Smallpox vaccine (1x10-8) with Dryvax Challenge at Day 112 Biological: ACAM3000 MVA Vaccine Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days Other Name: Dryvax smallpox vaccine Experimental: B MVA3000 Smallpox vaccine (1x10-8

2004 Clinical Trials

1484. Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the Eye

, patients return for follow-up visits once a month for 6 months. At these visits, several of the exams described above are repeated to evaluate treatment effects and check for adverse side effects. After 6 months, the implant is surgically removed. Post-surgical care for both implant and explant surgeries include examinations the day and week after surgery to examine the wound, a high dose of steroid immediately after surgery, oral antibiotics for 7 days, and eye drops for 1 week to prevent infection (...) be eligible for this study. Candidates will be screened with a medical history, physical examination, eye examinations, and eye photographs. The eye examination includes measurement of visual acuity and eye pressure, examination of the pupils and eye movements, and examination of the lens and back of the eye. In addition, patients will have the following tests: Visual field test: Patients look at a central spot on a white screen and tell the examiner whenever they see a small light appear at other places

2003 Clinical Trials

1485. Vertebroplasty for the Treatment of Fractures Due to Osteoporosis

options for osteoporotic vertebral compression fractures, the practice of percutaneous vertebroplasty, which involves injection of polymethylmethacrylate (medical cement) into the fractured vertebra, has disseminated rapidly. However, evidence for the efficacy of percutaneous vertebroplasty is currently limited to uncontrolled, nonblinded, small case studies. Even though high rates of success are reported, with up to 90% of patients achieving substantial pain relief, these case studies have (...) Participants will receive percutaneous vertebroplasty Device: Percutaneous vertebroplasty Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture Placebo Comparator: Control Group Participants will receive sham vertebroplasty without PMMA Procedure: Sham vertebroplasty Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed. Outcome Measures Go to Primary Outcome Measures

2003 Clinical Trials

1486. P38 Mitogen-activated Protein (Map) Kinase Inhibitor (SB-681323)Study In Patients With Neuropathic Pain

allodynia was determined using a 26 g von Frey filament. In a non-painful area, investigator repeatedly applied filament perpendicularly to skin, exerting enough pressure to make filament bend slightly, each time closer to presumed border of allodynia. When participant reported sensation becoming more unpleasant or painful, point at which filament was contacting the painful area of skin was marked with a felt tip pen by investigator. At that point, if participant's painful area was on a limb, a total (...) and repetitive, stimulation or pain in response to stroking lightly. Area of dynamic allodynia was determined using a one inch foam brush. In a non-painful area, investigator, exerted enough pressure to make foam brush bend slightly, would slowly move brush forward toward painful area of participant, at rate of 1 centimeter per second. When participant reported sensation becoming unpleasant or painful, point at which foam brush was contacting painful area of skin was marked with a felt tip pen

2006 Clinical Trials

1487. Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0, unless affected area has been removed surgically. Any of the following concurrent severe and/or uncontrolled medical conditions which could compromise participation in the study: Uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen; Unstable angina; New York Heart Association (NYHA) greater than/equal to grade 2 congestive heart failure Myocardial (...) : March 2011 Resource links provided by the National Library of Medicine related topics: available for: Arms and Interventions Go to Arm Intervention/treatment Experimental: FOLFIRI plus Bevacizumab FOLFIRI [folinic acid (leucovorin) 400 mg/m^2 by vein (IV) Day 1; 5-FU 400 mg/m^2 IV injection Day 1 immediately followed by 2.4 g/m^2 IV over 46 hours over Days 1-3; Irinotecan 180 mg/m^2 IV on Day 1] + Bevacizumab 5 mg/kg over 90 minutes on Day 1 administered alone then 5 mg/kg IV on Day 1 of 14 day

2006 Clinical Trials

1488. Bevacizumab and Erlotinib in Treating Patients With Advanced Liver Cancer

or similar tear production test) No stroke or transient ischemic attack within the past 6 months No uncontrolled high blood pressure, history of labile hypertension, or history of poor compliance with an antihypertensive regimen No unstable angina pectoris within the past 6 months No symptomatic congestive heart failure No myocardial infarction within the past 6 months No serious uncontrolled cardiac arrhythmias No uncontrolled diabetes mellitus No active or uncontrolled infection No impaired GI function (...) or disease that may significantly alter the absorption of erlotinib hydrochloride (e.g., ulcerative disease, uncontrolled nausea, vomiting, or diarrhea, malabsorption syndrome, or bowel obstruction) Able to swallow tablets No psychiatric illness or social situation that would limit compliance with study requirements No history of nephrotic-range protein No history of bleeding diathesis No encephalopathy No serious nonhealing wounds, skin ulcers, or bone fractures No clinically significant peripheral

2006 Clinical Trials

1489. Factors affecting the outcome of trabeculectomy: an analysis based on combined data from two phase III studies of an antibody to transforming growth factor beta2, CAT-152. (PubMed)

the treatment groups.Data were from patients (n = 726) with a diagnosis of primary open-angle glaucoma, chronic angle-closure glaucoma, pseudoexfoliative glaucoma, or pigmentary glaucoma (PG) who had an intraocular pressure (IOP) > 21 mmHg and visual field or optic disc changes characteristic of glaucoma and were taking the maximum tolerated dose of medication before trabeculectomy.Patients had trabeculectomy and 4 subconjunctival injections of a human monoclonal antibody to TGF-beta2 (CAT-152) or a placebo (...) . The definition of trabeculectomy success in the protocols was an IOP between 6 and 16 mmHg inclusive at months 6 and 12. Analyses of success used factors identified by ophthalmic experts.Covariates analyzed included patient age, black race, gender, time since diagnosis, primary diagnosis, country, diabetes, mean defect, cup-to-disc (C/D) ratio, suture type, anesthetic, flap type, IOP at listing for surgery, suture release/lysis, needling, reformed anterior chamber, wound leak, severe bleb vascularity

2007 Ophthalmology

1490. NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension (PubMed)

and UDCA on liver fibrosis and portal hypertension induced by i.p. injection of carbon tetrachloride in rats. Our results demonstrated that although both treatments reduced liver collagen deposition, NCX-1000, but not UDCA, prevented ascite formation and reduced intrahepatic resistance in carbon tetrachloride-treated rats as measured by assessing portal perfusion pressure. In contrast to UDCA, NCX-1000 inhibited HSC contraction and exerted a relaxing effect similar to the NO donor S-nitroso-N (...) NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension Portal hypertension resulting from increased intrahepatic resistance is a common complication of chronic liver diseases and a leading cause of death in patients with liver cirrhosis, a scarring process of the liver that includes components of both increased fibrogenesis and wound contraction. A reduced production of nitric oxide (NO) resulting

Full Text available with Trip Pro

2001 Proceedings of the National Academy of Sciences of the United States of America

1491. Bevacizumab to Treat Inflammatory Breast Cancer or Locally Advanced Breast Cancer

history of stroke, primary brain tumor or seizures not controlled by standard medical therapy. History of an active malignancy other than in situ carcinoma of the cervix, or non-melanomatous skin cancers in the last five years prior to Day 1 on study. Patients with non-healing wounds, bone fractures, or major surgery within the previous 28 days.. Uncontrolled hypertension (sustained systolic blood pressure greater than 160 mmHg or diastolic blood pressure of greater than 100 mmHg). Clinically (...) breast cancer. A small piece of tumor tissue and a small piece of skin from the affected breast are removed under local anesthesia for microscopic study. Dynamic MRI to examine changes in the blood vessels and breast cancer following bevacizumab treatment. This test involves injecting a contrast liquid into a vein before scanning. A standard MRI scan is done before the dynamic MRI. Blood tests are done to 1) study clot formation and breakdown, 2) measure levels of VEGF (a substance produced by breast

2001 Clinical Trials

1492. Single-dose antibiotic prophylaxis in maxillofacial surgery. (PubMed)

Single-dose antibiotic prophylaxis in maxillofacial surgery. The clinical efficacy of short-term antimicrobial prophylaxis with either one shot of ceftriaxone (1 g) or a course of 3 injections of a fixed combination of mezlocillin (2 g) and oxacillin (1 g) administered over 24 h was studied in a prospective randomized clinical study of 100 patients undergoing elective maxillofacial surgery. Tissue and plasma concentrations of the antibiotics were determined by high-pressure liquid (...) chromatography in 6 tumor surgery patients from each treatment group. Statistical analysis showed the treatment group to be comparable both demographically and with respect to the types of surgery performed and the durations of the procedures. Only 1 patient in each group developed a postoperative wound infection. It is concluded that 1 g ceftriaxone given 30 min preoperatively meets the pharmacokinetic requirements for perioperative antimicrobial prophylaxis in maxillofacial surgery.

1994 Chemotherapy Controlled trial quality: uncertain

1493. A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts

A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search (...) for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Trial of Bevacizumab in Myelodysplastic Syndromes (Int-1, Int-2 and High Risk According to International Prognostic Scoring System (IPSS)) With Excess of Marrow Blasts The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been

2007 Clinical Trials

1494. Study to Show Equivalence of DERMABOND PROTAPE to DERMABOND HVD for Wound Closure

Lacerations Device: cyanoacrylate with pressure sensitive mesh Device: cyanoacrylate Phase 2 Detailed Description: According to the literature, cyanoacrylate adhesives (topical skin adhesive) have performed as intended and have not produced results that would bring into question the safety or effectiveness of cyanoacrylate adhesive for closure of surgical incisions and traumatic wounds in humans. As such, this is a multicenter, prospective, randomized controlled study for the purpose of comparing two (...) : Arms and Interventions Go to Arm Intervention/treatment Experimental: Dermabond Protape DERMABOND PROTAPE (Prineo) Topical Skin Adhesive Device: cyanoacrylate with pressure sensitive mesh Topical Skin Adhesive Other Names: Dermabond Protape Prineo Active Comparator: Dermabond HVD DERMABOND HVD Topical Skin Adhesive Device: cyanoacrylate Topical Skin Adhesive Other Names: Dermabond - HVD Dermabond - Protape Outcome Measures Go to Primary Outcome Measures : The Incidence of Wound Closure Post

2007 Clinical Trials

1495. [Nuclear medicine studies of tissue concentration and hemodynamic effects of retrograde intravenous pressure infusions]. (PubMed)

intraarterial and 7 times higher than after intravenous injection of the same dose. The high count-rates which can be measured in the wound-secretion demonstrate the "rinsing effect" of the injected fluid. Hemodynamic investigations have been performed in a double blind study. 8 patients received buflomedil and 9 got placebo 3 times per week by retrograde intravenous pressure infusions. After 3 weeks there was an increase of the peak-flow on the lower leg (venous occlusion plethysmography), an increase (...) [Nuclear medicine studies of tissue concentration and hemodynamic effects of retrograde intravenous pressure infusions]. In 12 patients with trophic foot-lesions (diabetic feet) retrograde intravenous pressure infusions (150 ml) containing radioactive tracers (99m Tc, 99m Tc labelled human serum albumin) were carried out. With the veins emptied time-activity curves over the legs reflect tissue concentrations after release of the occlusion. Tissue-concentration is about 3 times higher than after

1993 Wiener medizinische Wochenschrift (1946) Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>